COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS

• Hoofdauteurs: R. I. Yagudina (Auteur), A. Yu. Kulikov (Auteur), I. A. Komarov (Auteur)
• Formaat: Boek
• Gepubliceerd in: IRBIS LLC, 2015-03-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Annually, all over the world there are 300 000 new patients with leukemia (approximately 3% of all oncology diseases), and mortality due to leukemia is 220 000 patients. Pharmacoeconomic evaluation of this pathology contributes to the improvement of approaches to treatment policy of this group of pa...